Show simple item record

dc.contributor.authorDodwell, David J
dc.contributor.authorWardley, Andrew M
dc.contributor.authorJohnston, S
dc.date.accessioned2009-07-06T10:22:28Z
dc.date.available2009-07-06T10:22:28Z
dc.date.issued2006-10
dc.identifier.citationPostmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. 2006, 15 (5):584-94 Breasten
dc.identifier.issn0960-9776
dc.identifier.pmid16504510
dc.identifier.doi10.1016/j.breast.2006.01.007
dc.identifier.urihttp://hdl.handle.net/10541/72534
dc.description.abstractAll patients receiving endocrine treatment for advanced breast cancer (ABC) eventually progress, resulting in a need for new therapies that lack cross-resistance with existing agents. Oestrogen receptor (ER) modulators such as toremifene and raloxifene have poor efficacy following tamoxifen failure, whereas the non-steroidal aromatase inhibitors (AIs), anastrozole and letrozole and the steroidal AI exemestane are effective. Fulvestrant is a new ER antagonist with no agonist effects that is as effective as anastrozole in treating patients who have progressed on tamoxifen. AIs are replacing tamoxifen as first-line treatments for ABC and in the adjuvant setting, necessitating a re-evaluation of optimal sequencing. Preliminary data suggest that tamoxifen, exemestane and fulvestrant have activity in patients who have progressed on non-steroidal AIs and hence could be considered for use in this setting. Due to the apparent lack of cross-resistance between non-steroidal and steroidal AIs, non-steroidal AIs could also be effective following steroidal AI failure. Clinical trials are underway to assess the most appropriate treatment sequence following non-steroidal AI failure, with comparisons of fulvestrant and exemestane of major interest.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAromatase Inhibitors
dc.subject.meshBreast Neoplasms
dc.subject.meshDecision Trees
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshEstradiol
dc.subject.meshEstrogen Receptor Modulators
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshPostmenopause
dc.subject.meshRaloxifene
dc.subject.meshTamoxifen
dc.titlePostmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.en
dc.typeArticleen
dc.contributor.departmentCookridge Hospital, Leeds LS16 6QB, West Yorkshire, UK. david.dodwell@leedsth.nhs.uken
dc.identifier.journalBreasten
html.description.abstractAll patients receiving endocrine treatment for advanced breast cancer (ABC) eventually progress, resulting in a need for new therapies that lack cross-resistance with existing agents. Oestrogen receptor (ER) modulators such as toremifene and raloxifene have poor efficacy following tamoxifen failure, whereas the non-steroidal aromatase inhibitors (AIs), anastrozole and letrozole and the steroidal AI exemestane are effective. Fulvestrant is a new ER antagonist with no agonist effects that is as effective as anastrozole in treating patients who have progressed on tamoxifen. AIs are replacing tamoxifen as first-line treatments for ABC and in the adjuvant setting, necessitating a re-evaluation of optimal sequencing. Preliminary data suggest that tamoxifen, exemestane and fulvestrant have activity in patients who have progressed on non-steroidal AIs and hence could be considered for use in this setting. Due to the apparent lack of cross-resistance between non-steroidal and steroidal AIs, non-steroidal AIs could also be effective following steroidal AI failure. Clinical trials are underway to assess the most appropriate treatment sequence following non-steroidal AI failure, with comparisons of fulvestrant and exemestane of major interest.


Files in this item

This item appears in the following Collection(s)

Show simple item record